SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
80>> Did exel get their money's worth? << tommysdad can tell us. scaram(o)uche-9/28/2004
79>> --lgnd, as its progenitor, took every opportunity to put distance bewtescaram(o)uche-9/28/2004
78>> Is xceptor's IP sound << Dunno. Good question. Came cheap.scaram(o)uche-9/28/2004
77Looking over xceptor's website, there are some intriguing kibbles. --the keokalani'nui-9/28/2004
76Ligand Agrees to Sell X-Ceptor Interest and to Vote Its X-Ceptor Shares in Favorscaram(o)uche-9/28/2004
75Exelixis Agrees to Acquire X-Ceptor Therapeutics Tuesday September 28, 6:00 am Enigel bates-9/28/2004
74Just learned Chiron of all companies has an oral multi-spectrum kinase inh in P1keokalani'nui-9/17/2004
73Sorry, phone call, partial post...to continue the thoughts XL999 inhibits the Fkeokalani'nui-9/2/2004
72[Note: SU11248 an oral, selective multi-targeted tyrosine kinase inhibitor withkeokalani'nui-9/2/2004
71Artemis Pharmaceuticals and Acceleron Pharma Cooperate in Mouse Genetics Cscaram(o)uche-8/27/2004
70<pre>Month Short Interest Percent Change Average Daily Share Volume Daysscaram(o)uche-8/25/2004
69Genentech Drug Linked to Deadly Clots Friday August 13, 3:10 pm ET By Susan Heakeokalani'nui-8/13/2004
68I listened to the replay. Interesting call. Scangos is good... very good.rkrw-8/12/2004
67Invitrogen Corporation and Exelixis Enter into Collaborative Research Agreement mopgcw-8/12/2004
66The Goldman Sachs Biotechnology Team will host a conference call tomorrow, Augusmopgcw-8/11/2004
65sorry, that was the piper report. you are right though: GS: EXEL (IL/N): Q2 imopgcw-8/9/2004
64?????We are maintaining our Outperform rating on Exelixis?????? I thought GS hakeokalani'nui-8/9/2004
63Exelixis, Inc. (EXEL - $7.16) Outperform Volatility: Medium Price: mopgcw-8/9/2004
62Exelixis Announces Second Quarter 2004 Financial Results Thursday August 5, 4:01mopgcw-8/5/2004
61<i>As a result of our second quarter 2004 restructuring, we are revising okeokalani'nui-8/5/2004
60<i>x999 P1 has started</i> In the current environment, that's pnigel bates-7/26/2004
59Exelixis Announces Second Quarter 2004 Financial Results and Outlook Conference keokalani'nui-7/26/2004
58The Goldman Sachs Biotechnology Team will host a conference call Thursday, July mopgcw-7/4/2004
57Exelixis Restructures to Focus Resources on Expanding Clinical Pipeline Wednesdascaram(o)uche-6/30/2004
56From piper: * This morning, before the open, Exelixis announced that it has filemopgcw-6/29/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News